Cargando…
Simulated driving performance in healthy adults after night‐time administration of 20 mg tasimelteon
An impairment in next day driving performance has been reported for almost every drug currently United States Food and Drug Administration (FDA) approved for improvement of sleep in chronic and transient insomnia. Tasimelteon, a melatonin receptor agonist, demonstrated significant improvements in ni...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285441/ https://www.ncbi.nlm.nih.gov/pubmed/34152055 http://dx.doi.org/10.1111/jsr.13430 |